PIR International was delighted to partner with Lidia Pieri and the Board at Sibylla Biotech on the appointment of Dieter Weinand as Chairman of the Board of Directors.
Sibylla is a preclinical stage company focused on developing small molecule degraders with a novel Mechanism of Action to find new therapeutics for unmet medical needs. Their platform is powered by computer simulations and AI methods, which enables the discovery and development of compounds that induce the degradation of a target protein by interfering with its folding pathway.
Dieter is an industry veteran, boasting over 35 years in the pharmaceutical sector, including leading business units and drug commercialisation initiatives at global organisations. His background includes serving as President, CEO and Chairman of the Board of Bayer Pharmaceuticals AG. At Sibylla, his profound knowledge will guide the Board as the company advances its innovative Pharmacological Protein Inactivation by Folding Intermediates Targeting (PPI-FIT) technology and pipeline of folding interference small molecules to address a range of challenging therapeutic areas.
Dieter holds a B.A. in Biology from Concordia College, New York, and an M.S. in Pharmacology and Toxicology from Long Island University, New York. He serves as Chairman of the Board at companies including Confo Therapeutics, DISCO Pharmaceuticals and FORE Biotherapeutics. In addition, he is the Lead Independent Director at Replimune (Nasdaq: REPL) and a Board Member at Coya Therapeutics (Nasdaq: COYA).
Lidia Pieri, PhD, MBA, Co-Founder and Chief Executive Officer of Sibylla Biotech, said: “Having an industry leader of Dieter’s stature head our Board underscores the potential of Sibylla’s technology to reshape the drug discovery landscape by unlocking access to a range of previously undruggable targets. Dieter’s demonstrated success in driving value from R&D to the commercialisation of impactful medicines will guide the next stages of Sibylla’s growth as we advance our pipeline of folding interference small molecules in preclinical studies. Personally, I will be honored to have him at our side.”
Dieter Weinand, Chairman of the Board of Sibylla Biotech, added: “Sibylla’s unique approach to targeting protein degradation during the folding process has the opportunity to revolutionise this field and open new avenues for recognised but currently inaccessible targets across high-need diseases. The company has made strides in growing the organisation, progressing its technology and securing strategic drug discovery collaborations. I look forward to working with the team to reach new corporate and clinical milestones.”
Click here to read more: Sibylla Biotech Appoints Former Bayer CEO, Dieter Weinand, as Chairman of the Board of Directors